PitchSend

Investor Presentaiton

. O • US Business US Business: Q3FY22 Sales of 5,731 million (YoY decline of 6.9%) US sales contributed 22.2% to total sales in Q3FY22 YoY decline was mainly on account of significant pricing pressure on the base business which was partially offset by new product launches In 9MFY22, the Company filed 9 ANDAs with the US FDA and received 18 approvals (including 3 tentative approvals) As on December 31, 2021, the Company has filed a total of 160 ANDAs (including 2 NDAs) with the US FDA and has received 124 approvals (including 15 tentative approvals and 2 NDAs) Q3FY22 US Sales (mn) - 6,156 YoY: (6.9)% 5,731 9MFY 22 - US Sales (mn) 19,078 YoY: (6.3)% 17,871 Q3FY21 Q3FY22 9MFY21 9MFY22 e ALKEM

View entire presentation